A Microfluidic Chip for Detecting Cholangiocarcinoma Cells in Human Bile

Bile liquid biopsy in biliary tract cancer

Biliary tract cancers are heterogeneous in etiology, morphology and molecular characteristics thus impacting disease management. Diagnosis is complex and prognosis poor. The advent of liquid biopsy has provided a unique approach to more thoroughly understand tumor biology in general and biliary tract cancers specifically. Due to their minimally invasive nature, liquid biopsy can be used to serially monitor disease progression and allow real-time monitoring of tumor genetic profiles as well as therapeutic response. Due to the unique anatomic location of biliary tract cancer, bile provides a promising biologic fluid for this purpose. This review focuses on the composition of bile and the use of these various components, ie, cells, extracellular vesicles, nucleic acids, proteins and metabolites as potential biomarkers. Based on the disease characteristics and research status of biliary tract cancer, considerable effort should be made to increase understanding of this disease, promote research and development into early diagnosis, develop efficient diagnostic, therapeutic and prognostic markers.

Cancer-on-chip: a 3D model for the study of the tumor microenvironment

The approval of anticancer therapeutic strategies is still slowed down by the lack of models able to faithfully reproduce in vivo cancer physiology. On one hand, the conventional in vitro models fail to recapitulate the organ and tissue structures, the fluid flows, and the mechanical stimuli characterizing the human body compartments. On the other hand, in vivo animal models cannot reproduce the typical human tumor microenvironment, essential to study cancer behavior and progression. This study reviews the cancer-on-chips as one of the most promising tools to model and investigate the tumor microenvironment and metastasis. We also described how cancer-on-chip devices have been developed and implemented to study the most common primary cancers and their metastatic sites. Pros and cons of this technology are then discussed highlighting the future challenges to close the gap between the pre-clinical and clinical studies and accelerate the approval of new anticancer therapies in humans.

A Design of Microfluidic Chip with Quasi-Bessel Beam Waveguide for Scattering Detection of Label-Free Cancer Cells

Light scattering detection in microfluidic chips provides an important tool to identify cancer cells without any label processes. However, forward small-angle scattering signals of cells, which are related to their sizes and morphologies, are hard to be detected accurately when scattering angle is less than 11° in microfluidic chips by traditional lighting design due to the influence of incident beam. Therefore, cell's size and morphology being the golden standard for clinical detection may lose their efficacy in recognizing cancer cells from healthy ones. In this article, a novel lighting design in microfluidic chips is put forward in which traditional incident Gaussian beam can be modulated into quasi-Bessel beam by a microprism and waveguide. The quasi-Bessel beam's advantages of nondiffraction theoretically make forward scattering (FS) detection less than 11° possibly. Our experimental results for peripheral blood lymphocytes of human beings and cultured HeLa cells show that the detection rates increase by 47.87% and 46.79%, respectively, by the novel designed microfluidic chip compared to traditional Gaussian lighting method in microfluidic chips. © 2019 International Society for Advancement of Cytometry.